SEC Form 4 · accession 0001209191-18-063604
Lineage Cell Therapeutics, Inc. · LCTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Russell Skibsted
Officer — Chief Financial Officer
Period of report
Dec 18, 2018
Accepted (ET)
Dec 20, 2018 · 8:40 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000876343
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Shares, no par valueF1,F2 | Dec 18, 2018 | M | 22,500 | $0.00 | A | 31,859 | D | |
| Common Shares, no par valueF3,F2 | Dec 18, 2018 | F | 7,781 | $1.03 | D | 24,078 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF4 | $0.00 | Dec 18, 2018 | M | 22,500 | D | — | — | Common Shares | 22,500 | 11,250 | D |
Explanation of responses
- F1Shares earned by the Reporting Person as a result of the vesting of Restrictive Stock Units ("RSUs") granted to the Reporting Person on May 24, 2018.
- F2Does not include RSUs payable in shares of the Issuer's common stock that have not vested as of the date of this Report and shares that may be acquired upon the exercise of certain stock options.
- F3Securities withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 22,500 RSUs, the grant of which was previously reported on a Form 8-K.
- F425% of the RSUs granted on May 24, 2018 vested on October 4, 2018, 50% of the RSUs vested on December 18, 2018, then the remaining 25% of the RSUs shall vest based on the sole determination by the Board of Directors that BioTime has achieved certain milestones, subject to the continuing employment of the Reporting Person on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person upon vesting.